

## Research Opportunities for C-type Natriuretic Peptide

**BioMarin Pharmaceutical Inc.** is a world leader in developing and commercialising **first- or best-in-class therapies for rare genetic diseases**. **C-type natriuretic peptide (CNP)** is a growth factor with receptors expressed in many cells and systems throughout the body (e.g., cardiovascular, pulmonary, central nervous system (CNS), musculoskeletal and reproductive tissues). BioMarin Pharmaceutical Inc. is seeking **early research ideas and preclinical proposals for CNP-related research projects**.



### Approaches of Interest

- Preclinical research applications that have an opportunity to address a serious unmet medical need. Applications in genetic diseases of the **musculoskeletal system, cardiovascular system, and CNS, as well as haematological diseases, are of the highest interest**
- CNP and its receptor transmembrane guanylyl cyclase receptor (NPRB) are expressed ubiquitously throughout many mammalian cells and tissues. **Targeted cells/tissues should express NPRB**
- Evidence of **MAP kinase pathway involvement or cGMP deficiency** in disease pathogenesis
- Diseases where **guanylyl cyclase agonists or MEK, phosphodiesterase and FGFR inhibitors** have been tested

### Out of Scope

- Certain research applications, including but not limited to aspects of cancer, growth deficiency, short stature, and approaches that require modifications to CNP may be excluded from this campaign

### Developmental Stages of Interest

- Opportunities at basic research phase to research phases prior to Phase I clinical trial are within scope
- Opportunities with *in vitro* (cell models), *in vivo* (animal models) or *ex vivo* experiments will be considered






### Submission Information

- Submission of either this [optional submission form](#) or alternatively one page, 200-300 words briefs are encouraged, along with any optional supplementary information (e.g., relevant publications, patents, slide decks)
- In submitting to this campaign, you confirm that your submission contains only **non-confidential** information

### Opportunity for Collaboration

BioMarin Pharmaceutical Inc. is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis.

## Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

## Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **11th April 2022 - 10:59 pm GMT**

### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)



BioMarin Pharmaceutical Inc. take pride in going where the science leads them, pioneering breakthrough treatments for debilitating and life-threatening conditions where they can significantly improve upon the current standard of care.